News

Nippon awarded exclusive rights in Japan to IPF treatment C21

Sweden-based Vicore Pharma has granted exclusive rights to pharmaceutical company Nippon Shinyaku to develop and commercialize its treatment candidate C21 (VP01) in Japan, with an initial focus on idiopathic pulmonary fibrosis (IPF). Nippon will be operationally and financially responsible for the development of C21 in Japan, where…

5 PFF Scholars each awarded $100K in research grants

Five new Pulmonary Fibrosis Foundation (PFF) scholars will each use $100,000, granted over the course of two years, to research new ways to diagnose, treat, or manage pulmonary fibrosis (PF). The six-year-old program awards grants each year to help scientists improve their understanding of PF, a chronic…

Broadway stars to belt out for PF fundraiser March 18

For the 14th year, a cast of Broadway luminaries will take the stage for the Pulmonary Fibrosis Foundation’s (PFF) largest fundraiser, Broadway Belts for PFF! The March 18 gala, which may also be viewed virtually, will raise funds and awareness for the more than 250,000 U.S. residents thought to…

Almee digital app shows promise in lowering anxiety in PF patients

Almee, an investigational app that offers personalized treatment to help people with pulmonary fibrosis (PF), was found to significantly reduce anxiety levels in PF patients who participated in a pivotal randomized study. Positive results from the COMPANION (NCT05330312) study were announced by Alex Therapeutics and Vicore…

Trevi launches Phase 2b trial of Haduvio for chronic cough

Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF). The Phase 2b trial, CORAL (NCT05964335), plans to enroll about 160 adults with IPF and chronic cough. No…